Podcasts about gastrointestinal cancers symposium

After the 2024 Gastrointestinal Cancers Symposium, Jun Gong, MD, and Daneng Li, MD, sat down to discuss the most relevant trial data to have come from the conference. They convened for a live X Space hosted by CancerNetwork®. During the discussion, they covered different trials across the gastrointestinal space, which included those evaluating different disease states from hepatocellular carcinoma (HCC) to colorectal cancer (CRC), and those assessing circulating tumor DNA (ctDNA) dynamics. Gong, a hematologic oncologist focusing on gastrointestinal and genitourinary cancers at Cedars-Sinai Medical Center, and Li, an associate professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, each gave their perspective on the clinical trial data and discussed if they had implemented any of these study treatments into clinical practice.  The studies they covered included:  1.        Phase 3 NETTER-2 Trial (NCT03972488)1: - Investigated lutetium Lu 177 dotatate (Lutathera) plus octreotide vs octreotide alone for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). - Lutetium Lu 177 significantly improved progression-free survival (PFS) and overall response rate (ORR) compared with octreotide alone. - The agent may be considered for patients with high-grade GEP-NETs who desire significant tumor shrinkage. 2.        Phase 3 EMERALD-1 Trial (NCT03778957)2: - Studied transarterial chemoembolization (TACE) plus durvalumab (Imfinzi) with or without bevacizumab (Avastin) for unresectable HCC. - Durvalumab/bevacizumab plus TACE improved PFS compared with placebo plus TACE. - TACE may be preferred over transarterial radioembolization (TARE) due to faster patient recovery. 3.        Phase 3 CheckMate-8HW Trial3: - Evaluated nivolumab (Opdivo) plus ipilimumab (Yervoy) vs chemotherapy for first-line treatment of microsatellite instability-high/mismatch repair deficient metastatic CRC. - Nivolumab/ipilimumab demonstrated superior PFS compared with chemotherapy. - Chemotherapy may no longer be the standard first-line treatment for this patient population. 4.        BESPOKE Study (NCT04264702)4: - Assessed the impact of minimal residual disease (MRD) detected by ctDNA on disease recurrence in patients with stage II and III CRC receiving adjuvant chemotherapy. - MRD positivity was associated with worse disease-free survival (DFS). - ctDNA clearance at 12 weeks indicated improved DFS.  5.        GALAXY Trial5: - ctDNA is a promising biomarker that can be used to predict recurrence in patients with CRC. - Patients with ctDNA-positive disease had a worse DFS than patients with ctDNA-negative disease. - This suggests that ctDNA may be useful for making treatment decisions, but more research is needed before it can be used in clinical practice. 6.        Phase 3 FRESCO-2 Trial (NCT04322539)6: - Fruquintinib (Fruzaqla) improved the quality of life in patients with metastatic CRC when combined with best supportive care and significantly improved quality-adjusted time without symptoms of disease or toxicity compared with placebo and best supportive care. - The study showed positive effects on PFS, response rate, disease control, and duration of response with the fruquintinib combination. - The findings from this trial supported the FDA approval of fruquintinib for metastatic CRC in November 2023.7 References 1.        Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase 3 randomized NETTER-2 study. J Clin Oncol. 2024(suppl 3):LBA588. doi:10.1200/JCO.2024.42.3_suppl.LBA588 2.        Lencioni R, Kudo M, Erinjeri J, et al. EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. J Clin Oncol. 2024;42(suppl 3):LBA432. doi.10.1200/JCO.2024.42.3_suppl.LBA432 3.        Andre T, Elez E, Van Cutsem E, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. J Clin Oncol. 2024;42(suppl_3):LBA768. doi.10.1200/JCO.2024.42.3_suppl.LBA768 4.        Kasi P, Aushev V, Ensor J, et al. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): interim analysis of BESPOKE CRC study. J Clin Oncol. 2024;42 (suppl _3):9. doi:10.1200/JCO.2024.42.3_suppl.9 5.        Yukami H, Nakamura Y, Mishima S, et al. Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN. J Clin Oncol. 2024;42(suppl_3):6. doi:10.1200/JCO.2024.42.3_suppl.6 6.        Stintzing S, Tabernero J, Satoh T, et al. Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): results from the FRESCO-2 trial. J Clin Oncol. 2024;42(suppl 3):116. doi:10.1200/JCO.2024.42.3_suppl.116 7.        FDA approves fruquintinib in refractory metastatic colorectal cancer. FDA. News release. November 8, 2023. Accessed February 7, 2024. https://shorturl.at/isJW2

It's been a busy few weeks here at CURE® and in the oncology space as a whole, as the last two weekends had back-to-back meetings: the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium, and then their Genitourinary Cancers Symposium.  Here are some highlights from the conference, but as always, you can find all of our coverage at curetoday.com.  Gastrointestinal Cancers Symposium  Imfinzi, Avastin, TACE May ‘Set a New Standard of Care' in Liver Cancer For patients with liver cancer whose disease is not eligible to be removed via surgery, adding Imfinzi and Avastin to transarterial chemoembolization — also known as TACE — tended to lengthen the time patients lived before their disease got worse, according to findings from the EMRALD-1 trial. These improvements in progression-free survival over TACE alone could lead to a new standard of care for this patient population, according to the lead study author, Dr. Riccardo Lencioni.  More specifically, patients who received Imfinzi and Avastin plus TACE lived for a median of 15 months before death or disease worsening, compared to 8.2 months for patients who received TACE alone. This correlates to a 23% reduction in the risk of disease progression or death, and benefits were seen across different patient subgroups.  Notably, the researchers on EMRALD-1 are still monitoring how the addition of the two drugs impacts overall survival. Once those data become more clear, it is possible that the drug manufacturers could submit this regimen to the FDA for approval, thereby officially shaking up the standard of care of TACE, which has remained the main treatment in this setting for about two decades.  Cancer in Bloodstream May Predict CRC Outcomes Circulating tumor DNA — also known as ctDNA — was another hot topic at the Gastrointestinal Cancers Symposium. So ctDNA measures little fragments of cancer that are found in the bloodstream after cancer treatment.  Now, findings from the BESPOKE trial highlight the fact that ctDNA may offer insight into the recurrence risk in patients with stage 2/3 colorectal cancer who underwent surgery and then chemotherapy. The researchers used ctDNA to help determine minimal residual disease, or MRD, status. Essentially, patients with disease still detected in the blood stream were MRD positive, while those without detectable cancer were MRD negative. Findings showed that those with MRD negativity tended to live longer without experiencing relapse or death compared to patients with MRD positivity.  Genitourinary Cancers Symposium Survival Benefits with Keytruda and Padcev in Advanced Urothelial Cancer Back in December, the Food and Drug Administration approved Padcev plus Keytruda for patients with previously treated locally advanced or metastatic bladder cancer. The approval was based on primary findings from the EV-302 trial. Now, updated findings from that trial are showing that the drug duo continues to outperform chemotherapy when it comes to progression-free survival — that's the time patients live before their disease gets worse — as well as overall survival, which is the time patients live before death of any cause.  Notably, these survival benefits were seen across patient subgroups, such as those with visceral metastases and lymph node-only disease. According to the lead study author, Dr. Michiel S. Van Der Heijden, this could result in a new standard of care in patients with locally advanced or metastatic urothelial carcinoma.  Many Patients Miss Out on Testing to Guide Prostate Cancer Treatment On the prostate cancer front, a study found that many people with metastatic castration-resistant prostate cancer are not undergoing germline or somatic testing. Now this is really important because back in 2020, two PARP inhibitors were approved in this setting. These are targeted drugs approved for patients whose cancers have certain characteristics, which can be determined by these types of tests.  Rates of germline and somatic testing have increased since the FDA approvals, but according to the study — which looked at real-world evidence of patients being treated in community cancer and urology centers — about 40% of patients did not undergo standard-of-care testing.  Study author, Dr. Neal Shore, said that this indicates the need for improved education on the importance of germline and somatic testing.  For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here. 

Last week, we saw some big headlines in the oncology space, from Dexter Scott King's death from prostate cancer and MLB Hall-of-Famer Ryne Sandberg announcing that he was diagnosed with the disease.  The FDA also requested a label update for CAR-T cell therapies that would warn patients and providers about secondary malignancies that have been reported from the treatment. Also, we took a look at laughter therapy, and how it could help patients and caregivers.  We've also been busy covering two conferences — ASCO's Gastrointestinal Cancers Symposium, as well as their Genitourinary Cancers Symposium, so tune in later this week for a special podcast episode highlighting some major research from those events.  Dexter Scott King Dies of Prostate Cancer, Ryne Sandberg Diagnosed With the Disease Last Monday, Jan. 22, we saw two big stories in the prostate cancer space. First, Dexter Scott King, the son of the Civil Rights activist, Martin Luther King, Jr., died of prostate cancer. He was 62 years old.  At the time of his death, King was the Chairman of the King Center, which is an organization focused on educating the world about the life and legacy of Dr. Martin Luther King Jr. Dexter Scott King was also the president of the King estate.  In a statement announcing King's death, his wife, Leah Weber said, “He transitioned peacefully in his sleep at home with me in Malibu. He gave it everything and battled this terrible disease until the end.”  And on the same day Dexter Scott King died, Major League Baseball Hall-of-Famer, Ryne Sandberg, announced that he was diagnosed with metastatic prostate cancer.  The 64-year-old — who was a 10-time All Star during his tenure for the Chicago Cubs, which ran from 1982 to 1997 — announced his diagnosis on Instagram. He said that received the diagnosis a week earlier and has started treatment. He asked that fans keep him in their thoughts and prayers.  FDA Requests Warnings on CAR-T Cell Therapies, Citing Secondary Cancers The investigation into CAR-T cell therapies continues. Recently, the Food and Drug Administration (FDA) requested that approved BCMA- or CD19-targeted CAR-T cell therapies update their labeling to include a warning of reports of T-cell malignancies, including CAR-positive lymphomas, which have been reported in patients who use this type of therapy.  Back in November, the FDA announced that it was investigating reports of secondary diseases in patients who underwent CAR-T cell therapy. The available data shows that these diseases are extremely rare, and researchers are still looking into what, exactly, is causing them.  Now, the FDA wrote letters to the manufacturers of five CAR-T cell therapies, requesting that they include a Boxed Warning — which is the highest safety-related warning for drugs — outlining the potential risks of CAR-T cell products. The companies must respond to the FDA within 30 days of receiving the letters, which were sent out on Jan. 19.  Laughter Therapy May Improve Mood, Decrease Pain in Patients With Cancer And on a much lighter note, we covered recent research showing that laughter therapy can decrease mood disturbances in patients receiving palliative care for late-stage cancer, as well as their loved ones. The findings, which were published in the journal, Cancer Nursing, also found that the laughter therapy reduced pain perception in patients and decreased levels of burnout in caregivers.  Laughter therapy refers to alternative and complementary therapy using humor to help relieve stress and pain, in addition to potentially improving a patient's sense of well-being, according to the National Cancer Institute. In this instance, it consisted of five 20- to 30-minute sessions held over five consecutive days. The participants introduced themselves using funny tools to relieve tension, and moved their bodies in laughing rhythms.  “This indicates that our palliative care patients and family caregivers would have a positive view of the use of laughter or humor in their palliative circumstances,” the researchers wrote.   For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

The 2023 ASCO Gastrointestinal Cancers Symposium took place from January 19 to 21 in San Francisco. On this episode, we're hearing from the presenting authors of three studies reported at that meeting—the SUNLIGHT, SPOTLIGHT, and NAPOLI-3 trials—which examined novel regimens in colorectal cancer, gastric cancer, and pancreatic cancer, respectively.To listen to more podcasts from ASCO, visit asco.org/podcasts.

Featuring perspectives from Dr Yelena Janjigian, Prof Eric Van Cutsem and Dr Harry Yoon, moderated by Dr Samuel Klempner, including the following topics:  Introduction (0:00) Current and Future Front-Line Management of Advanced Gastric and Gastroesophageal Junction (GEJ) Cancer — Yelena Y Janjigian, MD (3:11) Contemporary Management of HER2-Positive Advanced Gastric and GEJ Cancer — Eric Van Cutsem, MD, PhD (26:39) Selection and Sequencing of Therapy for Relapsed Gastric and GEJ Cancer — Samuel J Klempner, MD (46:31) Key Findings Informing the Treatment of Localized and Advanced Esophageal Cancer — Harry H Yoon, MD (1:08:11) CME information and select publications

Featuring perspectives from Prof Ghassan Abou-Alfa, Dr Richard Finn and Dr Robin Kelley, moderated by Dr Tanios Bekaii-Saab, including the following topics: Introduction (0:00) Advances in First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma (HCC) — Ghassan Abou-Alfa, MD, MBA (3:22) Selection and Sequencing of Therapy for Patients with Relapsed/Refractory HCC — Richard S Finn, MD (26:26) Current Treatment Strategies for Advanced Biliary Tract Cancers — Robin K Kelley, MD (46:53) Future Directions in the Management of Biliary Tract Cancer — Tanios Bekaii-Saab, MD (1:07:44) CME information and select publications

Featuring perspectives from Drs Kristen Ciombor, Cathy Eng, Pashtoon Kasi, Christopher Lieu and Alan Venook, including the following topics: Introduction (0:00) Current and Future Role of Therapies Targeting BRAF and HER2 in Metastatic Colorectal Cancer (mCRC) — Alan P Venook, MD (10:25) Integration of Immune Checkpoint Inhibitors into the Management of mCRC — Cathy Eng, MD (24:51) Selection and Sequencing of Therapy for Patients with Multiregimen-Refractory mCRC — Kristen K Ciombor, MD, MSCI (47:59) Other Considerations in the Management of Colorectal Cancer; Promising Investigational Strategies — Christopher Lieu, MD(1:11:40) CME information and select publications

The 2022 ASCO Gastrointestinal Cancers Symposium took place in San Francisco from January 20 to 22. This week, we're featuring commentary from the authors involved in two high-impact studies in hepatobiliary cancers.To listen to more podcasts from ASCO, visit asco.org/podcasts.

Proceedings from a webinar held in conjunction with the 2021 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Kristen K Ciombor and Eric Van Cutsem, moderated by Dr Neil Love.

Proceedings from a webinar held in conjunction with the 2021 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Kristen K Ciombor and Eric Van Cutsem, moderated by Dr Neil Love.

Proceedings from a webinar held in conjunction with the 2021 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Kristen K Ciombor and Eric Van Cutsem, moderated by Dr Neil Love.

Proceedings from a webinar held in conjunction with the 2021 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Daniel Catenacci, Yelena Y Janjigian, Rutika Mehta and Zev Wainberg, moderated by Dr Neil Love.

Proceedings from a webinar held in conjunction with the 2021 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Daniel Catenacci, Yelena Y Janjigian, Rutika Mehta and Zev Wainberg, moderated by Dr Neil Love.

Proceedings from a webinar held in conjunction with the 2021 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Daniel Catenacci, Yelena Y Janjigian, Rutika Mehta and Zev Wainberg, moderated by Dr Neil Love.

Proceedings from a webinar held in conjunction with the 2021 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Richard S Finn, Tim Greten, James J Harding, and Ahmed Omar Kaseb, moderated by Dr Neil Love.

Proceedings from a webinar held in conjunction with the 2021 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Richard S Finn, Tim Greten, James J Harding, and Ahmed Omar Kaseb, moderated by Dr Neil Love.

Proceedings from a webinar held in conjunction with the 2021 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Richard S Finn, Tim Greten, James J Harding, and Ahmed Omar Kaseb, moderated by Dr Neil Love.

La Dra. Marytere Herrera Martínez, oncólogo médico, adscrita al Servicio de Tumores Gastrointestinales en el Instituto Nacional de Cancerología, Ciudad de México, México, nos comenta sobre lo mejor del Gastrointestinal Cancers Symposium 2021, resaltando los siguientes estudios:

This week, we're back for more coverage of the 2021 Gastrointestinal Cancers Symposium, hearing about the FIGHT trial in advanced gastric/gastroesophageal junction adenocarcinoma, the ClarIDHy study in IDH1-mutated cholangiocarcinoma, and the POLO trial in BRCA-mutated pancreatic cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts.

In today's episode, Dr. Marcia Cruz-Correa, executive director of the University of Puerto Rico Comprehensive Cancer Center, discusses key abstracts from the 2021 Gastrointestinal Cancers Symposium.

The 2021 Gastrointestinal Cancers Symposium, held in a virtual format this year, is being held this weekend, January 15th to 17th, 2021. We're discussing findings from the meeting with three study authors.To listen to more podcasts from ASCO, visit asco.org/podcasts.

Proceedings from a CME symposium held at the 2020 Gastrointestinal Cancers Symposium. Featuring perspectives from Dr Ghassan Abou-Alfa, Dr Anthony El-Khoueiry, Dr Richard S Finn, Professor Dr Peter R Galle and Dr Andrew X Zhu. Introduction (00:00) First-Line Systemic Therapy for Patients with Unresectable Hepatocellular Carcinoma (HCC) — Dr Finn (16:35) Available Data with and Patient Selection for Anti-angiogenic Therapy for Progressive Metastatic HCC — Dr Zhu (47:41) Published Data with and Appropriate Integration of Immune Checkpoint Inhibitors into the Care of Patients with Progressive Metastatic HCC — Dr El-Khoueiry (1:07:51) Novel Approaches Under Investigation for Advanced HCC — Prof Galle (1:23:35) Current and Future Management of Advanced Biliary Tract Cancers — Dr Abou-Alfa (1:42:48) CME information and select publications

Proceedings from a CME symposium held at the 2020 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Crystal Denlinger, Howard S Hochster, John L Marshall, Michael J Overman, Philip A Philip and Prof Eric Van Cutsem. Introduction — Dr Neil Love (00:00) The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF V600E Tumor Mutations; HER2 and Other Potential Biomarkers — Dr Hochster (16:20) Lingering Questions in the Selection and Sequence of Therapy for Patients with mCRC — Dr Marshall (44:23) Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of mCRC — Dr Overman (1:05:39) Optimal Management of Metastatic Gastric/Gastroesophageal Cancer — Dr Denlinger (1:33:29) Contemporary Treatment Approaches for Patients with Pancreatic Cancer — Dr Philip (1:53:28) PARP Inhibition in Pancreatic Cancer; Promising Investigational Strategies — Prof Van Cutsem (2:15:15) CME information and select publications

The 2020 Gastrointestinal Cancers Symposium took place last weekend, and today, we'll take a deeper dive into findings in pancreatic cancer and colorectal cancer. We'll also review the FDA approval of tazemetostat in epithelioid sarcoma.Coverage of stories discussed this week on ascopost.com:‘Unprecedented' Responses to Cisplatin/Gemcitabine in BRCA-Mutated Advanced Pancreatic CancerFDA Approves Tazemetostat for Epithelioid Sarcoma

La Dra. Ivonne Salcedo Sullk hace un resúmen de los 8 artículos que le generaron mayor impacto en este congreso.

Meet The Professors: Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Colorectal, Gastric and Hepatocellular Cancer. Proceedings from a CME symposium held at the 2019 Gastrointestinal Cancers Symposium. Featuring perspectives on the following topics and cases from Dr Ghassan Abou-Alfa, Dr Peter C Enzinger, Dr Tim Greten, Dr David H Ilson, Dr Wells A Messersmith and Prof Eric Van Cutsem: Gastric and Gastroesophageal Cancer Case (Dr Enzinger): A 72-year-old woman with metastatic squamous cell carcinoma of the esophagus and a high PD-L1 combined positive score (CPS) receives third-line pembrolizumab (00:00) KEYNOTE-181: Results of a Phase III trial of pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal carcinoma (4:34) Sequencing anti-PD-1 checkpoint inhibitors for patients with metastatic HER2-negative gastric cancer and a PD-L1 CPS of 1 or higher (7:37) Case (Dr Ilson): A 71-year-old man with microsatellite-stable gastroesophageal junction (GEJ) adenocarcinoma and a high PD-L1 CPS (11:57) Research supporting the FDA approval of pembrolizumab for recurrent or advanced gastric or GEJ adenocarcinoma with a PD-L1 CPS of 1 or higher after 2 or more lines of chemotherapy (16:03) Clinical implications of the negative Phase III KEYNOTE-061 trial of pembrolizumab versus paclitaxel for previously treated advanced gastric or GEJ cancer (17:26) ATTRACTION-2: Results of a Phase III trial of nivolumab versus placebo for unresectable advanced or recurrent gastric or GEJ adenocarcinoma after at least 2 previous chemotherapy regimens (19:51) Second-line therapy options for patients with metastatic microsatellite-stable gastric cancer who experience disease progression on first-line FOLFOX (20:51) Results of the Phase III TAGS study: Efficacy, tolerability and potential clinical role of TAS-102 for patients with heavily pretreated metastatic gastric cancer (23:52) INTEGRATE: Results of a Phase II trial of regorafenib for patients with refractory gastric cancer (28:03) Select ongoing Phase III studies of other novel agents and strategies for metastatic gastric or GEJ cancer (30:30) Approach to second-line therapy for patients with metastatic HER2-positive, microsatellite-stable gastric cancer who experience disease progression on FOLFOX/trastuzumab (33:24) Case (Dr Enzinger): A man with moderately differentiated HER2-positive metastatic GEJ adenocarcinoma (35:18) Case (Dr Ilson): A 67-year-old woman with proximal gastric adenocarcinoma receives neoadjuvant FOLFOX (37:54)   Hepatocellular Carcinoma (HCC) Perspective on the recent advances in the treatment of HCC (42:10) Selection of first-line therapy for patients with HCC (46:05) Case (Dr Abou-Alfa): A 63-year-old man with a history of hepatitis C is diagnosed with HCC with metastasis to the bone (47:23) Choice of lenvatinib versus sorafenib as first-line therapy (50:15) Efficacy and tolerability of lenvatinib versus sorafenib as up-front therapy in the Phase III REFLECT trial (Study 304) (51:27) Therapeutic options for patients with HCC in the second-line setting (54:00) Results of the Phase III RESORCE trial of regorafenib for patients with unresectable HCC who experience disease progression on sorafenib (57:28) Case (Dr Abou-Alfa): A 71-year-old man with Stage IV hepatitis C-related HCC requires a dose reduction with second-line cabozantinib (59:42) Activity and side-effect profile of cabozantinib; results from the Phase III CELESTIAL trial of cabozantinib for patients with advanced HCC (1:00:59) Case (Dr Greten): A 72-year-old man with a history of hepatitis B and high alpha-fetoprotein (AFP) receives ramucirumab after disease progression on sorafenib (1:03:09) REACH-2: A Phase III study of ramucirumab as second-line treatment for patients with advanced HCC and elevated AFP after first-line sorafenib (1:04:05) Case (Dr Greten): A 37-year-old man with HCC metastatic to the omentum achieves a pathologic complete response with durvalumab (1:07:21) Role of molecular profiling for patients with HCC (1:11:18) KEYNOTE-224: A Phase II study of pembrolizumab in patients with advanced HCC previously treated with sorafenib (1:13:4) Activity of nivolumab in the Phase I/II CheckMate 040 study for patients with advanced HCC (1:15:47) Response and tolerability of atezolizumab/bevacizumab for patients with advanced HCC on a Phase Ib trial (1:17:14) Ongoing investigation of anti-PD-1/PD-L1 and anti-CTLA-4 combinations in HCC (1:19:52)   Colorectal Cancer (CRC) Treatment algorithm for metastatic CRC (mCRC) based on tumor sidedness and biomarker status (1:22:06) Efficacy and tolerability of anti-EGFR antibodies (1:26:52) Case (Prof Van Cutsem): A 59-year old woman with mCRC, a BRAF V600E mutation and microsatellite-stable disease receives cetuximab, encorafenib and binimetinib on the BEACON CRC trial after disease progression on FOLFOX/bevacizumab (1:31:07) Management of mCRC with a BRAF V600E mutation (1:33:42) Results of the SWOG S1406 trial of irinotecan and cetuximab with or without vemurafenib for mCRC with a BRAF mutation (1:37:13) Efficacy and safety of encorafenib, binimetinib and cetuximab in the Phase III BEACON CRC study for patients with mCRC and a BRAF V600E mutation (1:38:35) Case (Dr Messersmith): A 40-year old man with microsatellite instability (MSI)-high mCRC and Lynch syndrome achieves a near-complete response after receiving an anti-PD-L1 antibody on a clinical trial (1:40:16) Role of checkpoint inhibitors for patients with MSI-high mCRC (1:41:42) Efficacy of anti-PD-1/PD-L1 antibodies in patients with microsatellite-stable disease (1:45:40) Ongoing Phase III trials evaluating immune checkpoint inhibitors for patients with MSI-high mCRC (1:47:55) Case: A 56-year-old woman with mCRC and a KRAS exon 2 mutation receives regorafenib as third-line therapy (1:49:17) ReDOS: Optimal dosing of regorafenib in refractory mCRC; REVERCE: Sequencing of regorafenib and cetuximab for previously treated mCRC (1:57:01) Efficacy and safety of TAS-102 in mCRC (1:58:58)   Select publications

  Faculty presentations from a CME symposium held at the 2019 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Andrew E Hendifar, Eileen M O'Reilly, Philip A Philip and Margaret A Tempero: Available and Emerging Research Guiding the Treatment of Resectable or Borderline Resectable Pancreatic Adenocarcinoma (PAD) — Dr Tempero (0:00) Patient- and Disease-Specific Factors Informing the Selection of Therapy for Locally Advanced, Unresectable PAD; Selection of First-Line Treatment for Metastatic Disease — Dr Philip (8:24) Optimal Management of Metastatic Disease After Progression on First-Line Therapy — Dr O'Reilly (17:24) Novel Agents and Strategies Under Investigation — Dr Hendifar (25:21) Select publications

 Key Takeaways from the 2019 Gastrointestinal Cancers Symposium with Dr. Stephen Leong   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Welcome to the ASCO Daily News podcast. I'm Lauren Davis, and joining me today is Dr. Stephen Long, associate editor of ASCO Daily News. Dr. Long is associate professor in the division of medical oncology and is a translational researcher in the GI and developmental therapeutics programs at the University of Colorado Cancer Center. Dr. Long, welcome to the podcast. Thanks for having me. It's a pleasure to be here. Dr. Long, you've just returned from the Gastrointestinal Cancers Symposium. How was this year's event compared with previous years? First of all, I love you GI ASCO. I always find it informative. And I love the format of the talks and presentation. This year there was no significant practice changing presentations like in years past. However, there were still some excellent presentations and talks. And what were some of the presentations that stood out to you? There were some reports of a couple of clinical trials that sort of intrigued me. One was KEYNOTE-181. This was a phase III study comparing pembrolizumab monotherapy versus standard chemotherapy in patients with local events and metastatic esophageal cancer in the second line setting. They reported a significant improvement in overall survival in patients with PD-L1 combined positive score of greater than 10. And these patients received 9.3 months overall survival compared to 6.7 months for those who received [INAUDIBLE] choice of chemotherapy, which then consists of paclitaxel, docetaxel, or irinotecan. In addition, pembrolizumab was better tolerated and had a better safety profile. What made it really intriguing was of the total 628 patients that were enrolled in the trial, 64% of them had squamous cell carcinoma of the esophagus, which is unusual, especially in a phase II setting. And even though the study had a statistic overall survival benefit, in the squamous cell carcinoma cohort, there was a non-statistical trend in overall survival of 8.2 months versus 7.1 respectively. Pembrolizumab did boost the objective response rate compared with chemotherapy in the PD-L1 CPS greater than 10 and a response rate of 21.5% versus 6.1%. And then squamous cell carcinoma, it was 16.7% versus 7.4%. That leads to a whole bunch of questions. One, should we improve our PD-L1 scoring by including a CPX score greater than 10 and making our predictions based off that? In addition, should pembrolizumab expand its indications to include squamous cell carcinoma, since presently in the United States, pembrolizumab is only approved for adenocarcinoma. Also, there were the reports of the phase II ROAR study, which was looking at biliary tract cancers with BRAF V600E activating mutations. And these patients received a combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor. There were 33 patients. And they had an objective response rate of 42%. All of them with partial responses. And 7 of the 14 patients with responses had the responses lasting more than six months. And adding those with stable disease, they had reported a disease control rate of 88%. They looked at survival data. And the median progression free survival in this cohort was 9.2 months with an overall survival of 11.7 months. And to put this into context, usually second line biliary tract cancers we rarely ever see survival being more than five months. And these PFS and overall survival is very comparable to the first line setting for gemcitabine cisplatin, where the original study showed a PFS of eight months and overall survival of 11.7 months. So this potentially could be another treatment option for people with V600E biliary tract cancers. And then there were the preliminary results of a single phase II study at Memorial Sloan Kettering, which was evaluating pembrolizumab in conjunction with trastuzumab HER2 antibody with CAPOX and those with HER2 positive metastatic esophageal gastric adenocarcinoma. They had 32 patients with the overall response rate of 87%. They reported three CRs and 25 partial responses. And then when you factor in the stable disease, they had 100% disease control rate. And all the patients had some degree of tumor regression. The PFS were 11.4 months with an overall survival having not been met after six months. This is extremely exciting, and this has already led to the development of a global phase III study, which will be known as KEYNOTE-811. That's great. That sounds very promising. Were there any research presentations that you were interested in? Oh, yeah. There was a lot of great preclinical work. One of the most intriguing was in pancreatic cancer, where the Canadians did a study known as COMPASS, where they took advanced pancreatic ductal adenocarcinoma, and these patients underwent whole genome sequencing, as well as RNA sequencing of their tumors, prior to the initiation of first line chemotherapy with either modified FOLFIRINOX or gemcitabine and abraxane. Treatment outcomes were then compared to their molecular characteristics. The data suggests that chemotherapy differs depending on the transcription features of the tumor. So for example, the best survival data came out of those patients with the classical ductal adenocarcinoma subtype that were treated with FOLFIRINOX. And they had a median survival of 7.17 months. And when they were compared to the basal-like subtypes and were treated with FOLFIRINOX, they had a median progression free survival of 2.5 months. Now, patients with the basal-like subtype actually had a better response to gemcitabine and abraxane, which had a PFS of 5.65 months compared to the classical subtype, where they had median progression free survival of 4.93 months. So in summary, those with the basal-like subtype actually had a resistance for FOLFIRINOX. In addition, the researchers also mentioned that GATA6 RNA expression significantly correlates to the PDAC classic and basal-like molecular subtype. So it could actually be used as a marker in determining subtypes. And all this put together means that we could potentially identify patients who have a better chance of responding to FOLFIRINOX versus gem abraxane in the first line setting in pancreatic cancer. And obviously there needs to be more work to validate this, but this actually is quite intriguing. Also, there was data from the amino scoring testing, which was looking at its test in high risk stage 2 colorectal cancer patients. And for those who are not familiar, patients with stage colon cancer have a poor prognostic if they had a T4 disease, had fewer than 12 lymph nodes removed, had a point differentiation subtype, and also had evidence of vascular emboli, lymphovascular invasion, perineural invasion, or actually had a presentation of bowel obstruction or bowel perforation. And these patients are often offered adjuvant chemotherapy following curative resection due to their high risk of recurrence. The amino score test measures the density of CT3 positive T cells, as well as cytotoxic CDH cells within and surrounding the tumor to gauge the strength of the host immune response at a tumor site. So therefore a high amino score indicates a high anti-tumor immunity, which correlates with a low risk for disease recurrence. And these investigators looked at 1,130 patients with stage two colon cancers. And their conclusion for time to recurrence was those with high risk disease with high amino scoring compared to those with low risk disease had a very similar five-year survival of 87.4% versus 89.1% respectively. In contrast, if you have a high risk disease and a low amino scoring, your five-year time to recurrence was only 72.2% in the absence of adjuvant therapy. So this could potentially be used as a prognostic tool for those who are high risk stage two in the future. What about education sessions? Were there any that caught your attention? So my favorite was the neuroendocrine session. Neuroendocrine, as most people know, is a pretty rare disease population. However, there has been significant advances in the past few years with new drugs, new understanding of the biology, new diagnostic procedures, as well as testing. And it was a great panel of leading experts to help us navigate the new landscape of neuroendocrine and understanding how we should be approaching this. So that was my favorite session. Were there any other takeaways that were important during the symposium? There were a few other presentations I thought that were quite interesting. The Japanese presented their Prep-02 or JSAP-05 trial. And this was the first study to ever demonstrate the efficacy of neoadjuvant therapy in resectable pancreatic cancer. And their neoadjuvant chemotherapy regimen was a combination of gemcitabine with an oral drug S1. And they showed that it met its primary endpoint of overall survival of 36.72 months in those patients who received neoadjuvant therapy versus 26.65 months in those who went from upfront surgery. And for the Japanese, which tend to do upfront surgery followed by adjuvant chemotherapy in the past, I think this may be a shift in their paradigm, where this could be the new standard in Japan of using neoadjuvant therapy prior to surgery. Also, there was the oral drug trifluridine and tipiracil, which was studied in a phase III metastatic gastric and GE junction adenocarcinoma for those who have received two previous line of therapies. And they were randomized to the drug versus placebo. And it demonstrated a 2.1 survival benefit over placebo. And their main concern was a lot of these patients end up getting gastrectomies. But being an oral drug, could that affect its efficacy? And it seems like this benefit was also seen in those who had a gastrectomy versus those who didn't as well. So this potentially could be another option for those in the third line setting for gastric cancer. However, the big debate is even though it met its overall survival, is 2.1 months clinically significant? And I guess we'll have to have more data regarding safety and tolerability before we can make that decision. There is also the French GRECCAR-6 trial, which was evaluating the optimal time to surgery following chemoradiation for rectal cancer, where patients who underwent neoadjuvant chemoradiation were randomized to waiting 7 or 11 weeks prior to a mesoresection of the rectal cancer. They demonstrated that they had very similar path CR rates between the two. But more interesting, they found that if you had a good disease response to chemoradiation, there was no difference in disease free survival if you waited 7 weeks versus 11 weeks prior to surgery. However, if you were a bad disease responder, you had a poorer disease free survival if you waited more than seven weeks. However, this was not statistically significant. And then the authors concluded that we shouldn't be waiting more than seven weeks prior to surgery following neoadjuvant chemoradiation for rectal surgery. Thank you so much. Again, today my guest has been Dr. Stephen Long. Thank you for being on our podcast today. And to our listeners, thank you for tuning into the ASCO Daily News podcast. If you're enjoying the content, we encourage you to rate us and review us on Apple podcast.  

A critical review of key studies from the ASCO 2016 Gastrointestinal Cancers Symposium, held January 2016, is presented in this podcast. A number of tumor areas, including gastric, esophageal and colorectal cancers, are considered with an emphasis on recent developments in immunotherapy. Studies reviewed include the CheckMate-032 trial, which assessed the activity of the anti-PD-1 antibody nivolumab in patients with advanced gastric or gastroesophageal junction cancer, the KEYNOTE-028 trial, for which results of the esophageal carcinoma cohort treated with pembrolizumab were presented, and updated results of a trial considering PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. Biomarkers are further considered in the Mavericc trial which sought to stratify metastatic colorectal cancer patients by ERCC1 in order to predict their response to platinum-based treatments. Neoadjuvant therapy was considered with the results of a study, from the Polish Colorectal Study Group, using neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancers, and the 5-year follow up results of the ACCORD 12 trial, which aimed to assess an increased radiation dose plus oxaliplatin versus standard radiotherapy of 45 Gy with concurrent capecitabine in rectal cancer. These highlights are presented by Gerald W. Prager, Medical University of Vienna, Austria (gerald.prager@meduniwien.ac.at). The podcast is conducted by Anna Berghoff, Department of Medicine, Medical University of Vienna, Austria.

In this podcast, Dr. Smitha Krishnamurthi discusses three studies highlighted at the 2016 Gastrointestinal Cancers Symposium, which examined two new treatment options for people with advanced neuroendocrine tumors and a new pre-surgical treatment option for people with locally advanced rectal cancer.  Cancer Research News

In this podcast, we’ll discuss a study highlighted at the 2015 Gastrointestinal Cancers Symposium that examines the relationship between Vitamin D levels and survival in patients with advanced colorectal cancer.  Cancer Research News

In this podcast, we’ll review some of the news announced at the 2014 Gastrointestinal Cancers Symposium, co-sponsored by ASCO. Cancer Research News

Morton Kahlenberg, MD, discusses the research highlights from the 2012 Gastrointestinal Cancers Symposium in San Francisco, California, including research on pancreatic, colorectal, and esophageal cancers and neuroendocrine tumors. Cancer Research News

Morton Kahlenberg, MD, discusses the research highlights from the 2011 Gastrointestinal Cancers Symposium in San Francisco, California, including research on esophageal cancer, anal cancer, colorectal cancer, and gastrointestinal stromal tumor. Cancer Research News

Host: Mark Chyna, MD These Conference Coverage Highlights are from the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium, held January 22nd to the 24th in Orlando, Florida. The meeting presented more than 500 abstracts on gastrointestinal cancers affecting the esophagus, stomach, hepatobiliary system, pancreas, small bowel, colon and rectum.

Highlights of studies presented at the American Society of Clinical Oncology's 2009 Gastrointestinal Cancers Symposium, held January 15 through 17 in San Francisco.

ColorectalCancerUpdate.com/LiveThinkTank – Edited Proceedings from a CME Satellite Meeting at the Gastrointestinal Cancers Symposium in Orlando. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ColorectalCancerUpdate.com/LiveThinkTank – Edited Proceedings from a CME Satellite Meeting at the Gastrointestinal Cancers Symposium in Orlando. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ColorectalCancerUpdate.com/LiveThinkTank – Edited Proceedings from a CME Satellite Meeting at the Gastrointestinal Cancers Symposium in Orlando. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ColorectalCancerUpdate.com/LiveThinkTank – Edited Proceedings from a CME Satellite Meeting at the Gastrointestinal Cancers Symposium in Orlando. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ColorectalCancerUpdate.com/LiveThinkTank – Edited Proceedings from a CME Satellite Meeting at the Gastrointestinal Cancers Symposium in Orlando. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

ColorectalCancerUpdate.com/LiveThinkTank – Edited Proceedings from a CME Satellite Meeting at the Gastrointestinal Cancers Symposium in Orlando. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium

Proceedings from a CME Satellite Symposium at the Gastrointestinal Cancers Symposium